Effects of angiotensin receptor blocker, Candesartan on renal function in type 2 diabetes with chronic kidney disease and hypertension

Effects of angiotensin receptor blocker, Candesartan on renal function in type 2 diabetes with chronic kidney disease and hypertension - J-CARE

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002049

Enrollment

100

Registered

2009-06-05

Start date

2008-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes with chronic renal disease and hypertention

Interventions

Patients: Type 2 diabetes with hypertention (SBP&gt

=130 or DBP&gt

=80) and CKD (eGFR:30&lt

, 60&gt

= mL/min/1.73m2)under regular dose of ARB therapy Intervention: prospectively and randomly divided into two groups matched for age, gender, BMI, BP, and eGFR. Patients of Candesartan group received C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertensive type 2 diabates who were diagnosed by criteria of Japan Diabetes Society. SBP =>130mmHg or DBP=>80mmHg eGFR <60ml/min/1.73m2 =>40y.o. <80y.o. under treatment of small or regular dose of ARB

Exclusion criteria

Exclusion criteria: the patients who are not satisfied with key inclusion criteria.

Design outcomes

Primary

Measure	Time frame
eGFR 1 year after intervention	—

Secondary

Measure	Time frame
IMT, blood pressure (ratio of achievement in BP 130/80mmHg) urinary secretion of albumin, 1 year after intervention	—

Countries

Japan

Contacts

Public ContactHiroko Abe

Juntendo University School of Medicine Metabolism and Endocrinology, Department of Medicine

hirosemd@juntendo.ac.jp03-5802-1579

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026